<DOC>
	<DOCNO>NCT02426099</DOCNO>
	<brief_summary>This four-week randomized control single blind trial subject present resistant hypertension specialize diabetes care unit Cameroon . They randomly assign use method block treatment daily 25mg spironolactone routine intensification antihypertensive regimen , add previous regimen unchanged diet . Visits schedule start treatment , week two four follow add-on therapy initiation . The primary outcome change office self-measurement blood pressure record visit , secondary outcome variation serum potassium , sodium , creatinine level .</brief_summary>
	<brief_title>Efficacy Spironolactone Cameroonian Diabetic Patients With Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Resistant hypertension Diabetes mellitus T2DM overt acute/chronic complication , serum potassium ≥ 5.5 mmol/l , estimate Glomerular Filtration Rate ( eGFR ) calculate use Modification Diet Renal Disease formula ≤ 30 ml/min/1.73m² body weight , absolute contraindication drug regimen trial , current aldosterone antagonist treatment cessation within last 15 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Resistant hypertension</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>African</keyword>
</DOC>